Ballard, 2006^{1} | Placebo | 288 | Mean: 26 SD: 1.5 | Mean: 759 SD: 155 | W: 145 (50.3) B: 90 (31.3) H: 43 (14.9) Other: 10 (3.) | HFV: 74 (25.7) CMV: 191 (66.3) CPAP: 23 (8) | Median:16 Range:13-19 IQR Units: Days | NA | | |

iNO | 294 | Mean: 26 SD: 1.5 | Mean: 766 SD: 161 | W: 170 (57.8) B: 76 (25.9) H: 32 (10.9) Other: 16 (5.4) | HFV: 65 (22.1) CMV: 202 (68.7) CPAP: 27 (9.2) | Median:16 Range:12-19 IQR Units: Days | NA | 20ppm ×48-96hours: titrate every 7days for a minimum of 2 days exposure | |

Follow-up of Ballard, 2006^{1} Hibbs, 2007^{2} | Placebo | 225 | Mean: 25.7 SD: 1.5 | Mean: 762 SD: 150 | W: 121 (53.8) B: 64 (28.4) H: 31 (13.8) Other: 9 (4) | NA | NA | NA | | |

iNO | 230 | Mean: 25.8 SD: 1.4 | Mean: 769 SD: 163 | W: 141 (61.3) B: 56 (24.2) H: 22 (9.5) Other:: 11 (4.8) | NA | NA | NA | 20ppm: weaned over at least 24days | |

Follow-up of Ballard 2006^{1} Walsh, 2010^{3} | Placebo gas | 234 | Mean: 25.7 SD:1.5 | Mean: 764 SD: 153 | W: 124(53) Other: 110(47) | NA | Median: 16 Range: 13-20 IQR Unit: days | NA | | |

iNO | 243 | Mean:25.8 SD: 1.4 | Mean: 765 SD: 163 | W: 151(62) Other: 92(38) | NA | Median: 17 Range: 13-19 IQR Unit: days | NA | 20ppm ×24hours: decrease to 10ppm ×1week decrease to 5ppm ×1week decrease to 2ppm ×1week | |

Banks, 1999^{4} | iNO | 16 | Median: 25.5 Range: 24-29 | Median: 787 Range: 448-1790 | NA | HFV: 5 (31.25) CMV :11 (68.75) | Median: 2.5 Range: 1-7 Units: Months | NA | 20ppm ×72hours: responders weaned by 20% every 3day | |

Cheung, 1998^{5} | iNO treated cohort | 24 | Median: 25 Range: 24-27 (25% and 75 %) | Median: 860 Range: 668-1068 (25% and 75 %) | NA | CMV : 24 (100) | NA | Median:32 Range: 28-52 (25% and 75 %) | 20ppm: decrease by 5ppm within 2hours s/p initial dose decrease by 5ppm q15-30min to lowest dose w/+ response | |

Clark, 2002^{6} | iNO | 33 | Mean: 25.3; Range: 23-29 | Mean: 736 Range: 509-1250 | W: 11 (33) B: 21 (64) H: 1 (3) | | Mean: 19 Range: 9-29 Units: Days | | 20ppm ×36hours: decrease to 15ppm and decrease by 2-3ppm every1 2hours; discontinued by 7 days. | |

Dani, 2006^{7} | Control | 20 | Mean: 26.7 SD: 1.9 | Mean: 825 SD: 299 | NA | HFV: 11 (55) | NA | Mean: 15.1 SD: 4.9 | | |

iNO | 20 | Mean: 26.3 SD: 2.6 | Mean: 937 SD: 298 | NA | HFV: 10 (50) | NA | Mean:16.4 SD: 5.1 | 5ppm: Increase by 5ppm every 30min to max 15ppm | |

No responders | 6 | Mean: 25.4 SD: 2.6 | Mean: 748 SD: 321.4 | NA | CPAP: 4 (67) | NA | Mean:18.1 SD: 4.2 | 5ppm: Increase by 5ppm every 30min to max 15ppm | |

Responders | 14 | Mean: 26.7 SD: 1.9 | Mean: 1022.7 SD: 243.1 | NA | CPAP: 13 (93) | NA | Mean:14.7 SD: 3.9 | 5ppm: Increase by 5ppm every 30min to max 15ppm | |

Dewhurst, 2010^{8} | Responders | 26 | Median: 26 Range: 25-29 | Median: 920 Range: 655-1538 | NA | | Median: 53 Range: 37-217 Units: Hours | Median: 47 Range: 30-78 | 10ppm: titrated | |

Non-responders | 8 | Median: 29 Range: 27-30 | Median: 915 Range: 723-183 | NA | | Median: 75 Range: 20-183 Units: Hours | Median: 23 Range: 8-54 | 20ppm: titrated |

Field, 2005^{9} | Control | 53 | Mean: 26.3 SD: 2.4 | Mean: 890 SD: 343 | NA | HFV: 39 (74%) | Median: 1 Range: 1-5 IQR Units: Days | Median:31.9 Range: 17.4-51.8 IQR | | |

iNO | 55 | Mean: 27.4 SD: 2.6 | Mean: 1006 SD: 395 | NA | HFC: 33 (60) | Median: 1 Range: 0-6 IQR Units: Days | Median: 32.9 Range: 22.2-49.8 IQR, | 5ppm: double dose every 15min to max 40ppm | |

Follow-up of Field 2005^{9} Huddy, 2008^{10} | Control | 16 | Mean: 28.2 SD: 2.7 | Mean: 1142 SD: 440 | NA | NA | Median: 1 Range: IQR 1.5 Units: Days | Median: 25.9 Range: IQR 41.3 | | |

iNO | 22 | Mean: 28.5 SD: 2.4 | Mean: 1191 SD: 403 | NA | NA | Median: 1 Range: IQR 3 Units: Days | Median: 30.1 Range: IQR 20.5 | 5ppm: double dose every 15min until PaO2 increases >22.5mmHg to max 40ppm | |

Franco-Belgium Collaborativ e NO Trial Group, 1999^{11} | Control | 45 | Median: 29 Range: 3.1 IQR | Median: 1150 Range: 520 IQR | NA | HFV: 34 (76) CMV : 11 (24) | Median:1 Range: 1 IQR Units: Days | Median: 18 Range: 7.4 IQR | | |

iNO | 40 | Median: 29.6 Range: 2.6 IQR | Median: 1200 Range: 570 IQR | NA | HFV: 30 (75) CMV : 10 (25) | Range: 1.5 Units: Days | Median:20.2 Range: 8.3 IQR | 10ppm ×2-3hours: decreased to 5ppm then slowly wean off if deteriorating condition, increased dose to 20ppm | |

Hascoet, 2005^{12} | Control with hypoxemic respiratory failure | 84 | NA | BW<750: 19 (22) BW 750-999: 17 (20), BW 1000-1500: 32 (39) BW >1500: 16 (19) | NA | NA | NA | Mean:12 SD: 5.6 | | |

iNO with hypoxemic respiratory failure | 61 | NA | BW <750g: 10 (16.5) BW 750-999g: 14 (23) BW 1000-1500g: 27 (44) BW >1500g: 10 (16.5) | NA | NA | NA | OI Mean:14.6 SD: 8.9 | 5ppm: if aAO2 increase >0.22 decrease iNO to 2ppm if aAO2 increase <0.22 but >25% iNO remains at 5ppm if aAO2 unchanged increase iNO to 10ppm | |

Follow-up of Hascoet 2005^{12} Hamon, 2005^{13} | Hypoxemic respiratory failure, no iNO | 39 | Mean: 27.9 SD: 0.4 | Mean: 1102 SD: 54 | NA | NA | Mean:15.9 SD: 1.8 Units: Hours | NA | | |

iNO treated hypoxemic respiratory failure | 37 | Mean: 27.3 SD: 0.4 | Mean: 1083 SD: 58 | NA | NA | Mean:14.1 SD:1.4 Units: Hours | NA | 5ppm: aAO2 increase >0.22 decrease iNO to 2ppm aAO2 increase <0.22 but >25% iNO remains at 5ppm aAO2 unchanged increase iNO to 10ppm | Median: 35.1 hours |

Kinsella, 1999^{14} | Control | 32 | Mean: 26.8 SD: 2.5 | Mean: 988 SD: 387 | NA | NA | Mean: 27 SD:37 Units: Hours | NA | | |

iNO | 48 | Mean: 27.1 SD: 2.5 | Mean: 1040 SD: 461 | NA | NA | Mean:30 SD: 38 Units: Hours | NA | 5ppm × 7days: if OI increase >15%, iNO restarted | |

Kinsella, 2006^{15} | Placebo gas, Total sample | 395 | Mean: 25.6 SD: 1.8 | Mean: 788 SD: 185 | W: 234 of 394 (59.4) B: 98 of 394 (24.9) H: 48 of 394 (12.2) Other: 14 of 394 (3.6) | HFV: 113 of389 (29) CMV : 276 of 389 (71) | Mean:30.1 SD:13.2 Units: Hours | Mean:5.8, SD:6.7 | | |

iNO, Total sample | 398 | Mean: 25.6 SD: 1.7 | Mean: 796 SD: 190 | W: 249 of 397(62.7) B: 94 of 397(23.7) H: 41 of 397(10.3) Other: 13 of 397 (3.3) | HFV: 113 of 393 (28.8) CMV : 280 of 393 (71.2) | Mean:30.5 SD:13.4 Units: Hours | Mean:5.4 SD: 5.2 | 5ppm × 21days | Median: 14 days |

Follow-up of Kinsella 2006^{15} Watson, 2009^{16} | Control-detailed outcome cohort | 320 | Mean: 25.7 SD: 1.9 | Mean: 791 SD: 186 | W: 192 (60) B: 71 (22.2) H: 44 (13.8) Asian/Other: 13 (4.1) | NA | NA | Median:4.1 Range: 2.7-6.4 IQR | | |

iNO-detailed outcome cohort | 332 | Mean: 25.6 SD: 1.7 | Mean: 797 SD: 190 | W: 205 (61.8) B: 76 (22.9) H: 38 (11,5) Asian/Other: 13 (3.9) | NA | NA | Median:4.1 Range: 2.8-6.2 IQR | 5ppm ×21days or until extubated | |

Mercier, 2010^{17} | Control | 401 | Mean: 26.6 SD: 1.3 | Mean: 864 SD: 192 | W: 328 (82) B: 48 (12) A: 2 (<1) Other: 23 (6) | CPAP: 42 (10) | NA | Mean: 8.6 SD: 12.7 | 5ppm | |

iNO | 399 | Mean: 26.4 SD: 1.3 | Mean: 851 SD: 207 | W: 329 (82) B: 39 (10) A: 4 (1) Other: 27 (7) | CPAP: 41 (10) | NA | Mean: 8.0 SD: 10.7 | 5ppm | |

Schreiber, 2003^{18} | Placebo | 102 | Mean: 27 SD: 2.8 | Mean: 949 SD: 387 | W: 12 (11.8) B: 74 (72.6) Other: 16 (15.7) | HFV: 48 (47) CMV: 54 (52.9) | Median:114 Range: IQR 7.6-28.5 | Median:6.8 Range: 4.4-12.7 IQR | | |

iNO | | 105 | Mean: 27.4 SD: 2.5 | Mean: 1017 SD: 369 | W: 18 (17.1) B: 71 (67.6) Other: 16 (15.2) | HFV: 54 (51.4) CMV: 51 (48.6) | Median: 12.9 Range: IQR 7.0-25.2 | Median:7.3 Range: IQR 4.1-12.3 | 10ppm ×12-24hours: decrease to 5ppm and hold 6day or 1 hour before extubation if Pa02 decrease by 15%, restart NO and decrease by 1 ppm every 6hours | |

Follow-up of Schreiber, 2003^{18} Mestan, 2005^{19} | Control | 68 | Mean: 27.2 SD: 2.6 | Mean: 958 SD: 356 | W: 8 (12) B: 52 (76) Other:: 8 (12) | NA | SD: 8.4 Units: Months | Median: 7.2 Range: IQR 4.5-14.3 | | |

iNO | 70 | Mean: 27.5 SD: 2.4 | Mean: 1026 SD: 366 | W: 14 (20) B: 44 (63), Other:: 12 (17) | NA | Mean: 24.9 SD: 7.9 Units: Months | Median: 6.6 Range: IQR 4-11.5 | 10ppm ×24hours: decrease to 5ppm and hold 6d or 1 hours before extubation | |

Srisuparp, 2002^{20} | Control | 18 | Mean: 27.2 SD: 0.5 | Mean: 901 SD: 73 | B: 16 (89) | HFV: 7 (38.9) | NA | Mean:11.9 SD: 2.2 | | |

iNO | 16 | Mean: 26.8 SD: 0.5 | Mean: 874 SD: 70 | B: 16 (100) | HFV: 7 (43.8) | NA | Mean:10.8 SD: 1.5 | 20ppm ×6-12hours: decrease to 10ppm ×12hours decrease to 5ppm ×12hours decrease by 1ppm every 12hours | |

Su, 2008^{21} | Received inhaled oxygen placebo only | 33 | Mean: 27.9 SD: 1.8 | Mean: 1050 SD: 210 | NA | NA | Mean:2.5 SD: 1.8 Units: Days | Mean: 30.5 SD: 4.7 | | |

iNO | 32 | Mean: 27.4 SD: 2.3 | Mean: 1020 SD: 230 | NA | CMV : 32(100) | Mean: 2.45 SD: 1.7 Units: Days | Mean:30.3 SD: 3.5 | 5ppm ×6hours: if + response, decrease 1ppm every 6hours to min 1ppm if – response, increase 5ppm every 6hours to max. 20ppm | Mean: 4.9 SD: 2.3 Unit: days |

Subhedar, 1997^{22} | Dexamethasone and standard of care | 22 | Median: 27 Range: 22-31 | Median: 750 Range: 520-1400 | NA | NA | Median: 104 Range: 96-120 Units: Hours | Median: 3.9 Range: 1.2-11.5 | | |

iNO + iNO and dexamethasone) | 20 | Median: 27 Range: 24-30 | Median: 882 Range: 416-1354 | NA | NA | Median: 99 Range: 96-113 IQR Units: Hours | Median: 7.9 Range: 1.6-46.7 | 20ppm: iNo started at 20ppm, given for 2 hours, if responsive weaned by 5 ppm every 15 minutes until 5ppm then continued for 72 hours, then discontinued. | |

Dexamethasone alone AND dex + iNO) | 21 | Median: 27 Range: 22-31 | Median: 870 Range: 530-1400 | NA | NA | Median: 104 Range: 96-120 Units: Hours | Median: 7.9 Range: 1.2-46.7 | 20ppm: iNo started at 20ppm, given for 2 hours, if responsive weaned by 5 ppm every 15 minutes until 5ppm then continued for 72 hours, then discontinued. | |

iNO AND standard of care | 21 | Median: 27 Range: 22-31 | Median: 818 Range: 520-1222 | NA | NA | Median: 98 Range: 96-114 Units: Hours | Median: 4.1 Range: 1.4-28 | 20ppm: iNo started at 20ppm, given for 2 hours, if responsive weaned by 5 ppm every 15 minutes until 5ppm then continued for 72 hours, then discontinued. | ` |

Follow-up of Subhedar, 1997^{22} Bennett, 2001^{23} | Control | 22 | NA | NA | NA | CMV :22 (100) | Mean: 96 Units: Hours | NA | | |

iNO | 20 | NA | NA | NA | CMV :20 (100) | Mean: 96 Units: Hours | NA | 5-20ppm iNO × 72hours or until extubated | |

Tanaka, 2007^{24} | Control | 15 | Median: 26 Range: 24-30 | Median: 818 Range: 720-1400 IQR | NA | HFV: 9 (60) | NA | Median: 23.3 Range: 16-45 | | |

iNO | 16 | Median: 25.5 Range: 25-28.8 | Median: 838 Range: 628-1144 IQR | NA | HFV: 14 (87.5) | NA | Median: 23.3 Range: 16-45 IQR | 10ppm: Increase 10ppm every 30min to max 30ppm | |

Uga, 2004^{25} | Control | 10 | Mean: 25.8 SD: 2.4 Range: 24-30 | Mean: 809 SD: 316 Range: 426-1453 | NA | NA | NA | Mean: 13.9 SD: 10.2 | | |

iNO | 8 | Mean: 27.2 SD: 2.2 Range: 24-30 | Mean: 996 SD: 294 Range: 570-1317 | NA | NA | NA | Mean: 28.8 SD: 18.3 | 30-40ppm | |

Van Meurs, 2005^{26} | Control | 210 | Mean: 26 SD: 2 | Mean: 837 SD: 260 | W: 96 (46) B: 78 (37) H: 32 (15) Other: 4 (2) | HFV: 124 (59) CMV: 86 (41) | Mean:28 SD: 22 Units: Hours | Mean:22 SD:17 | | |

iNO | 210 | Mean: 26 SD: 2 | Mean: 840 SD: 264 | W: 95 (45) B: 69 (33) H: 36 (17) Other: 10 (5) | HFV: 125 (59) CMV : 85 (40) | Mean:26 SD: 23 Units: Hours | Mean:23 SD:17 | 5ppm: Hold if PaO2 increases >=20mmHg or increase to 10ppm | Mean: 76 SD: 73 Unit: hours |

Sub analysis of Van Meurs, 2005^{26} Chock, 2009^{27} | Control | 6 | Mean: 29 SD: 3 | Mean: 1179 SD: 369 | W: 4 (67) B: 1 (17) H: 0 (0) Other: 1 (17) | HFV: 6 (100) | Mean:11 SD: 4 Units: Hours | Mean:44 SD: 30 Median:39 Range:10-100 | | |

iNO | 6 | Mean: 27 SD: 2 | Mean: 1039 SD: 355 | W: 2 (33) B: 1 (17) H: 2 (33) Other: 1 (17) | HFV: 6 (100) | Mean:12 SD: 8 Units: Hours | Mean:20 SD:27 Median: 19 Range: 11-64 | 5ppm ×30min: increase 5ppm if PaO2 did not increase >20mmHg | Mean: 1 SD: 0.2 Unit: hours |

Follow-up of Van Meurs, 2005^{26} Hintz, 2007^{28} | Placebo | 102 | Mean: 26.2 SD: 2.2 | Mean: 864 SD: 271 | W: 46 (45) B: 35 (34) H: 18 (18) Other: 1 (1) | HFV: 57 (56) | NA | Mean: 18.1 SD:1 1.3 Median: 149 Range:.5 - 21.6 | | Median: 2 Range: 1-75 IQR Unit: hours |

iNO Follow-up of group | 91 | Mean: 26.8 SD: 2.3 | Mean: 958 SD: 276 | W: 43 (47) B: 27 (30) H: 17 (19) | HFV: 61 (67) | NA | Mean: 20 SD:12.9 Median: 16.3 Range: 12-24 | 5ppm titrated | Median:72 Range: 42-115IQR |

Van Meurs, 2007^{29} | Control | 15 | Mean: 31.4 SD: 1.1 | Mean: 2168 SD: 441 | W: 5 (33) B: 4 (27) H: 6 (40) | HFV: 11 (73) CMV : 2(13) HFFI: 2 (13) | NA | Mean: 28.2 SD:17.3 | | |

iNO | 14 | Mean: 31.1 SD: 1.2 | Mean: 1970 SD: 391 | W: 7 (50) B: 5 (36) H: 1 (7) Other:1 (7) | HFV: 6 (43) CMV : 8 (57) HFFI 0 (0) | NA | Mean:25.1 SD:19.4 | 5ppm ×30min: Increase to 10ppm | |

Yadav, 1999^{30} | iNO | 41 | Mean:27 SD:2.6 | Mean: 1000 SD: 46 | NA | NA | NA | Mean: 40 SD: 17 | 10ppm | |